[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microbiology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microbiology":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,74,95,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100646761","longitudinal-evaluation-of-several-modalities-of-treatment-of-peri-implantitis-5-to-23-years-follow-up-100646761",false,"NCT07684001","Longitudinal Evaluation of Several Modalities of Treatment of Peri-implantitis: 5 to 23 Years Follow-up","longitudinal","Inclusion Criteria:The sample included 300 systemically healthy individuals, over 18 years of age, who received some type of treatment (surgical or non-surgical) for peri-implantitis, associated or not with systemic antibiotic therapy. Subjects cannot have undergone periodontal treatment for at least 6 months prior to the start of the study; agree to participate in the study and agree to sign the ICF.\n\n\\-\n\nExclusion Criteria:Individuals who have lost the treated implants after some peri-implant therapy and those who do not accept to sign the ICF will be excluded.\n\n\\-",true,"ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","To evaluate the peri-implant conditions of patients undergoing different surgical and non-surgical techniques, associated or not with regenerative therapies after long periods of time (between 5 and 23 years)\n\n3\\. MATERIAL AND METHODS\n\n3.1. Experimental design This retrospective study will evaluate the peri-implant conditions of patients with peri-implantitis treated at the UnG Clinic using various types of treatments. To this end, participants will be selected from the UnG graduate clinic who received some type of treatment (surgical or non-surgical) until 2021. Participants selected for the study must sign the Informed Consent Form (ICF) after verbal and written explanation of the project. Subjects will receive oral hygiene instruction and professional prophylaxis prior to clinical examinations.\n\n3.2. Sample selection This clinical study will be submitted for approval by the Ethics Committee of the University of Guarulhos (CEP-UnG). Subjects (minimum of 50 and maximum of 300) will be recruited and evaluated at the Implantology clinic of Guarulhos University. This sample was obtained based on the power test so that the study presented a power of around 80%, and NCI and bone loss were considered primary variables.\n\n3.3. Inclusion criteria The sample included 300 systemically healthy individuals, over 18 years of age, who received some type of treatment (surgical or non-surgical) for peri-implantitis, associated or not with systemic antibiotic therapy.\n\n3.4. Sample exclusion criteria Individuals who have lost the implants after some peri-implant therapy;' have undergone periodontal treatment for at least 6 months prior to the start of the study.\n\nClinical examinations A single, trained and calibrated examiner will perform all clinical examinations. The examiner will be trained and calibrated before and during the study in order to achieve maximum reproducibility in measurements. The methodology to be used for intra-examiner calibration will be the one recommended by Araujo et al. 2003, in which the standard error of measurement for continuous periodontal clinical parameters is evaluated. For the other clinical variables, the mean level of agreement between the examiners will be determined and considered satisfactory when the value is greater than 90% (Kappa test).\n\nClinical measures\n\nThe following parameters will be recorded at six sites per implant using a periodontal probe North Carolina:\n\n1. Plate index: 0 = absence of plaque; 1 = separate patches of plaque at the cervical margin; 2 = a thin, continuous band of plaque \\[up to 1 mm\\] at the cervical margin of the tooth; 3 = strip of plaque greater than 1 mm, but covering less than 1\u002F3 of the tooth crown; 4 = plaque that covers at least 1\u002F3 but less than 2\u002F3 of the tooth's crown; 5 = plate covering 2\u002F3 or more of the tooth's crown).\n2. Gingival index : 0 = absence of inflammation; 1 = mild inflammation change in color and little change in texture; 2 = moderate inflammation - tempered glasses, redness, edema and hypertrophy; 3 = severe inflammation - marked redness and hyperplasia.\n3. Bleeding on probing: 0 = absence; 1 = presence.\n4. Suppuration: 0 = absence; 1 = presence.\n5. Probing depth: distance (mm) from the peri-implant mucosal margin to the most apical portion of the peri-implant pocket.\n6. Relative attachment level: distance (mm) from the implant shoulder to the most apical portion of the peri-implant pocket.\n7. Keratinized tissue height : vertical distance (mm) measured from the mucogingival line to the peri-implant margin in the center of the buccal face of the implant.\n8. Keratinized tissue thickness 1: measured in the center of the buccal surface of the ridge, at the midpoint between the mucogingival line and the top of the ridge.\n9. Mesial and distal keratinized tissue thickness 2: measured over the ridge (mesial and distal of the implant) when the crown can be removed.\n10. Evaluation of the biotype of peri-implant tissue: thin or thick, according to the visualization of the periodontal probe through the peri-implant tissue.\n\nScrew-retained implant crowns will be removed to observe clinical records, while cemented crowns will not be removed.\n\nRadiographic measurements As a way of evaluating the stability of bone tissue, the interproximal level of the bone crest will be measured by means of periapical radiographs. After the radiographic takes, the radiographs will be scanned and the distance in millimeters from the interproximal bone crest to the base of the implant will be evaluated.",[25,26],"Periodontal Disease","Microbiology",[28,29],"peri-implantitis","periodontal diseases","NOT_YET_RECRUITING","2026-07-03",{"date":33,"type":34},"2026-07-07","ACTUAL",{"date":36,"type":21},"2026-06-29",{"date":38,"type":21},"2027-03-29",{"name":40,"class":41},"University of Guarulhos","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100645298","etiologic-diagnosis-algorithm-in-infective-endocarditis-100645298","NCT07682389","Etiologic Diagnosis Algorithm in Infective Endocarditis","Development and Validation of An Algorithm of Etiological Diagnosis of Infective Endocarditis in Adults: An Open-Label Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Informed consent,\n* Age ≥ 18,\n* IE (definite or possible per the 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis)\n\nExclusion Criteria:\n\n* Pregnancy\u002Fbreastfeeding\n* Unconfirmed or rejected IE diagnosis,\n* Very high risk of death within 14 days due to severe complications of the main or concomitant disease(s), according to the physician's opinion;\n* Prior use of antibiotic therapy (except documented treatment failure).",{"count":50,"type":21},128,"INTERVENTIONAL",[53],"NA","The goal of this study is to evaluate the impact of a diagnostic algorithm combining culture-based and molecular methods on the frequency of etiotropic antibiotic therapy prescription within 14 days of diagnosis of infective endocarditis",[56,26],"Infective Endocarditis",[58,59,60,61,62],"Infective endocarditis","PCR","Antibiotic therapy","Etiological diagnosis","Sequencing","RECRUITING","2026-06-28",{"date":66,"type":34},"2026-07-02",{"date":68,"type":34},"2026-01-20",{"date":70,"type":21},"2027-02-20",{"name":72,"class":41},"I.M. Sechenov First Moscow State Medical University",3,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100623134","optimisation-of-the-blood-culture-pathway-utilising-behaviour-change-100623134","NCT07392684","Optimisation of the Blood Culture Pathway Utilising Behaviour Change","Inclusion Criteria:\n\nSecondary data:\n\n\\- adult blood culture sets received in the microbiology laboratory, between February 2023 and April 2024.\n\nStaff member participants\n\n\\- Staff members that collect adult blood cultures within the Trust\n\nExclusion Criteria:\n\nSecondary data:\n\n* paediatric blood culture samples\n* samples where volume, collection and\u002For time to incubation data are not recorded on laboratory system and\u002For blood culture analyser",{"count":81,"type":21},24,"Blood culture (BC) is the gold standard for the definitive diagnosis of bacteraemia, providing the opportunity to recover and identify the causative organism, and optimize subsequent antimicrobial treatment. Detection of bacteraemia is critical for the management of sepsis. This study aims to examine the performance of the blood culture pathway in Gloucestershire Hospitals Trust using data analysis, questionnaires and focus groups. . Information collected will be used to design interventions that could be used to optimise the blood culture pathway",[26,84],"Blood Culture","2026-01-29",{"date":87,"type":34},"2026-02-06",{"date":89,"type":34},"2025-10-01",{"date":91,"type":21},"2026-09-30",{"name":93,"class":41},"Gloucestershire Hospitals NHS Foundation Trust",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":51,"phases":105,"briefSummary":106,"conditions":107,"keywords":122,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100609268","infant-microbiota-restoration-with-maternal-microbes-100609268","NCT07212361","Infant Microbiota Restoration With Maternal Microbes","MaMi","Inclusion Criteria:\n\n* Healthy mother and healthy pregnancy\n* Singleton pregnancy,\n* Mothers who speak Finnish or Swedish\n* Mothers who are planning to breastfeed or give breastmilk by bottle to the infant\n* Infants who are expected to be healthy and who will not require BCG vaccination.\n\nExclusion Criteria:\n\n* Participants who lives further than a 2-hour drive from Meilahti, Helsinki, Finland\n* Mothers who are not planning to breastfeed or feed breastmilk by bottle to the infant\n* Mothers who are diagnosed with gestational diabetes, pre-eclampsia or who have been receiving antibiotics during the pregnancy or delivery\n* Premature infants born before the pregnancy week 37\n* Infants, who are born by urgent cesarean section or emergency cesarean section\n* Infants, who receive antibiotics during the first week of life\n* Infants, who are diagnosed with a disease, congenital anomaly or who receive less than 9 Apgar points at 5 minutes.\n* Infants, who receive BCG-vaccine","50 Years",{"count":104,"type":21},100,[53],"The goal of this clinical trial is to test the ability of different bacterial products in restoring natural gut microbiota in C-section born infants. The main question it aims to answer is:\n\nDo maternally derived strains of bacteria perform better than commercially available probiotic strains in restoring the gut microbiota of C-section born infants? Researchers will compare the gut microbiota of treated infants to that of untreated C-section born infants and untreated vaginally born infants to see if the bacterial treatments cause the microbiota to resemble that of vaginally born infants.\n\nParticipants will be given a bacterial product orally once daily for either one or four weeks and be asked to collect faecal, urine and saliva samples.",[108,109,110,111,112,113,114,115,116,117,118,26,119,120,121],"Infant, Newborn","Gut -Microbiota","Gut Dysbiosis","Cesarean Delivery Affecting Newborn","Cesarean Section","Vaginal Delivery","Gastrointestinal Microbiota","Microbiota, Cesarean Section, Probiotics, Dysbiosis","Feces","Delivery, Obstetric","Microbiota","Humans","Pregnancy","Neonate",[123,124,125,126,127,128],"Infant","newborn","cesarean section","neonate","restore","gut microbiota","2025-09-30",{"date":131,"type":34},"2025-10-08",{"date":133,"type":34},"2025-07-17",{"date":135,"type":21},"2035-12-31",{"name":137,"class":41},"University of Helsinki",2,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":51,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":94},"100528669","appropriate-use-of-blood-cultures-in-the-emergency-department-through-machine-learning-100528669","NCT06163781","Appropriate Use of Blood Cultures in the Emergency Department Through Machine Learning","Appropriate Use of Blood Cultures in the Emergency Department Through Machine Learning: a Randomized Controlled Trial","ABC","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Have a clinical indication for a blood culture analysis (according to the treating physician)\n* Have sufficient data recorded (laboratory results and vital sign measurements) for a prediction to be made (at least 20% of the needed parameters)\n\nExclusion Criteria:\n\n* Central Venous Line (CVL) or Peripherally Inserted Central Catheter (PICC) in situ\n* Neutrophil count \\\u003C 0.5 \\* 109\u002FL\n* Candidemia or S. aureus bacteraemia in the past 3 months.\n* Most likely diagnosis of endocarditis\u002Fspondylodiscitis\u002Finfected prosthetic material\n* Pregnant or breastfeeding patients\n* Not capable of giving informed consent",{"count":148,"type":21},7584,[53],"The goal of this clinical trial is to study whether the use of our blood culture prediction tool is non-inferior to current practice and if it can improve certain outcomes in all adult patients presenting to the emergency department with a clinical indication for a blood culture analysis (according to the treating physician). The primary endpoint is 30-day mortality. Key secondary outcomes are:\n\n* hospital admission rates\n* in-hospital mortality\n* hospital length-of-stay. In the intervention group, the physician will follow the advice of our blood culture prediction tool.\n\nIn the comparison group all patients will undergo a blood culture analysis.",[152,153,26,154,155],"Artificial Intelligence","Machine Learning","Emergency Service, Hospital","Randomized Controlled Trial","2024-05-03",{"date":158,"type":34},"2024-05-07",{"date":160,"type":34},"2024-02-19",{"date":162,"type":21},"2027-07",{"name":164,"class":41},"Amsterdam UMC, location VUmc"]